Elicio Therapeutics Inc ELTX
📋 Company Profile
| Industry | Biotechnology |
| Country | US |
| Exchange | NASDAQ NMS - GLOBAL MARKET |
| Currency | USD |
| IPO Date | 2021-02-05 |
| Shares Out. | 23,020,000 |
| Website | elicio.com/ ↗ |
| Phone | 13026587581 |
| Employees | 33 |
| Net Income | -$11.8M |
| Free Cash Flow | -$38.5M |
| Total Assets | $22.7M |
| Total Liabilities | $24.1M |
| Equity | -$1.4M |
About Elicio Therapeutics Inc
Elicio Therapeutics Inc is a clinical-stage biotechnology company advancing novel immunotherapies for the treatment of cancer, including mKRAS-positive pancreatic cancer, colorectal cancer (CRC), lung cancer, and other mKRAS-positive cancers. The Company focuses on developing effective, off-the-shelf immunotherapies using its proprietary Amphiphile (AMP) technology, which aims to enhance the education, activation, and amplification of cancer-specific T cells to promote durable cancer immunosurveillance. Its clinical pipeline includes ELI-002 7P, a lymph node-targeted cancer immunotherapy currently being evaluated in a Phase 2 study for mKRAS pancreatic ductal adenocarcinoma (PDAC), a common form of pancreatic cancer.
Elicio Therapeutics Inc is a publicly traded company under the ticker symbol ELTX on the NASDAQ NMS - GLOBAL MARKET, operating in the Biotechnology industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.
📊 Analyst Ratings
10 analysts (2026-07-01)